

## Contents

**Preface** XI

**List of Contributors** XIII

**Introduction** 1

**1 The Significance of Heterocycles for Pharmaceuticals  
and Agrochemicals** 3

*Clemens Lamberth and Jürgen Dinges*

- 1.1 Introduction 3
- 1.2 Heterocycles as Framework of Biologically Active Compounds 4
- 1.3 Fine-Tuning the Physicochemical Properties with Heterocycles 6
- 1.4 Heterocycles as Prodrugs 6
- 1.5 Heterocycles as Peptidomimetics 7
- 1.6 Heterocycles as Isosteric Replacement of Functional Groups 8
- 1.7 Heterocycles as Isosteric Replacement of Alicyclic Rings 11
- 1.8 Heterocycles as Isosteric Replacement of other Heterocyclic Rings 13
- References 16

**Part I Neurological Disorders** 21

**2 Tropane-Based Alkaloids as Muscarinic Antagonists  
for the Treatment of Asthma, Obstructive Pulmonary Disease,  
and Motion Sickness** 23

*Michael L. Schulte and Craig W. Lindsley*

- 2.1 Introduction 23
- 2.2 History 23
- 2.3 Synthesis 25
- 2.4 Mode of Action 29
- 2.5 Structure–Activity Relationships 32
- References 34

<b>3</b>	<b>Morphinone-Based Opioid Receptor Agonist Analgesics</b>	<b>37</b>
	<i>Stephanie M. Ng</i>	
3.1	Introduction	37
3.2	History	37
3.3	Synthesis	40
3.4	Mode of Action	43
3.5	Structure–Activity Relationship	44
	References	48
<b>4</b>	<b>Barbituric Acid-Based GABA(A) Receptor Modulators for the Treatment of Sleep Disorder and Epilepsy and as Anesthetics</b>	<b>51</b>
	<i>Ingo Janser and Romy Janser</i>	
4.1	Introduction	51
4.2	History	52
4.2.1	Barbiturates in the Treatment of Sleep Disorders	55
4.2.2	Barbiturates in the Treatment of Epilepsy	55
4.2.3	Barbiturates as Anesthetics	56
4.3	Synthesis	57
4.4	Mode of Action	60
4.5	Structure–Activity Relationship	62
4.5.1	5,5-Disubstitution	62
4.5.2	Substitution at the Nitrogens	63
	References	63
<b>5</b>	<b>Phenothiazine-Based Dopamine D<sub>2</sub> Antagonists for the Treatment of Schizophrenia</b>	<b>65</b>
	<i>Cristiana A. Zaharia</i>	
5.1	Introduction	65
5.2	History	65
5.3	Synthesis	70
5.4	Mode of Action	72
5.5	Structure–Activity Relationships	76
	References	77
<b>6</b>	<b>Arylpiperazine-Based 5-HT<sub>1A</sub> Receptor Partial Agonists and 5-HT<sub>2A</sub> Antagonists for the Treatment of Autism, Depression, Anxiety, Psychosis, and Schizophrenia</b>	<b>81</b>
	<i>Irini Akritopoulou-Zanze</i>	
6.1	Introduction	81
6.2	History	81
6.3	Synthesis	85
6.4	Mode of Action	88
6.5	Structure–Activity Relationship	89
	References	96

**7 Arylpiperidine-Based Dopamine D<sub>2</sub> Antagonists/5-HT<sub>2A</sub> Antagonists for the Treatment of Autism, Depression, Schizophrenia, and Bipolar Disorder 99**

*Ying Wang*

- 7.1 Introduction 99
- 7.2 History 99
- 7.3 Synthesis 106
- 7.4 Mode of Action 109
- 7.5 Structure–Activity Relationship 111
- References 113

**8 Dibenzazepine-Based Sodium Channel Blockers for the Treatment of Neuropathic Pain 115**

*Derek W. Nelson*

- 8.1 Introduction 115
- 8.2 History 115
- 8.3 Synthesis 119
- 8.4 Mode of Action 124
- 8.5 Structure–Activity Relationships 128
- References 130

**Part II Cardiovascular Diseases 135**

**9 Dihydropyridine-Based Calcium Channel Blockers for the Treatment of Angina Pectoris and Hypertension 137**

*Milan Bruncko*

- 9.1 Introduction 137
- 9.2 History 139
- 9.3 Synthesis 141
- 9.4 Mode of Action 144
- 9.5 Structure–Activity Relationship 148
- References 149

**10 Tetrazole-Based Angiotensin II Type 1 (AT<sub>1</sub>) Antagonists for the Treatment of Heart Failure and Congestive Hypertension 153**

*Edward C. Lawson, Brian C. Shook, and James C. Lanter*

- 10.1 Introduction 153
- 10.2 History 154
- 10.3 Synthesis 157
- 10.4 Mode of Action 159
- 10.5 Structure–Activity Relationship 161
- References 163

**11      Thiazide-Based Diuretics for the Treatment of Hypertension and Genitourinary Disorders   169***Jürgen Dinges*

- 11.1    Introduction   169
- 11.2    History   169
- 11.3    Synthesis   174
- 11.4    Mode of Action   177
- 11.5    Structure–Activity Relationship   179
- References   180

**12      Tetrahydropyranone-Based HMG-CoA Reductase Inhibitors for the Treatment of Arterial Hypercholesterolemia   183***Hongyu Zhao*

- 12.1    Introduction   183
- 12.2    History   183
- 12.3    Synthesis   188
- 12.4    Mode of Action   191
- 12.5    Structure–Activity Relationship   192
- 12.5.1   The Hydrophilic Dihydroxypentanoic Acid Portion   192
- 12.5.2   The SAR of Natural Statins   192
- 12.5.3   SAR of Synthetic Statins   195
- 12.5.4   Liver-Selective HMGC<sub>o</sub>A Inhibitors   197
- 12.5.5   X-Ray Crystal Structures   197
- References   198

**Part III    Infectious Diseases   201****13      Adenine-Based Reverse Transcriptase Inhibitors as Anti-HIV Agents   203***Alastair Donald*

- 13.1    Introduction   203
- 13.2    History   203
- 13.3    Synthesis   209
- 13.4    Mode of Action   212
- 13.5    Structure–Activity Relationship   212
- References   214

**14      Guanine-Based Nucleoside Analogs as Antiviral Agents   217***Maurizio Franzini*

- 14.1    Introduction   217
- 14.2    History   219
- 14.3    Synthesis   221
- 14.4    Mode of Action   227
- 14.5    Structure–Activity Relationship   229
- References   232

**15 Penicillin and Cephalosporin Antibiotics 237***Michael Z. Hoemann*

- 15.1 Introduction 237
- 15.2 History 237
- 15.3 Synthesis 239
  - 15.3.1 Total Syntheses 239
  - 15.3.2 Core Modifications 243
- 15.4 Mode of Action 248
- 15.5 Structure–Activity Relationships 250
- References 251

**Part IV Oncology 255****16 Pyrimidine-Based Kinase Inhibitors in Cancer Chemotherapy 257***Robert Mah*

- 16.1 Introduction 257
- 16.2 History 257
- 16.3 Synthesis 261
- 16.4 Mode of Action 264
- 16.5 Structure–Activity Relationship 266
- References 269

**17 Benzyl Triazole-Based Aromatase Inhibitors for the Treatment of Breast Cancer 275***Dawn George and Stacy Van Epps*

- 17.1 Introduction 275
- 17.2 History 275
- 17.3 Synthesis 277
- 17.4 Mode of Action 281
- 17.5 Structure–Activity Relationship 282
- References 286

**Part V Inflammation and Gastrointestinal Diseases 289****18 Acetonide-Based Glucocorticoids for the Treatment of Asthma, Skin Inflammation, and Diseases of the Eye 291***Kevin P. Cusack, Vikram G. Kalthod, Rajarathnam E. Reddy, and Sanjay R. Chemburkar*

- 18.1 Introduction 291
- 18.2 History 293
- 18.3 Synthesis 297
- 18.4 Mode of Action 304
  - 18.4.1 Asthma 306
  - 18.4.2 Skin Inflammation 307
  - 18.4.3 Eye Disease 307

18.5	Structure–Activity Relationship	308
	References	311

## 19      **Benzimidazole-Based $H^+/K^+$ -ATPase Inhibitors for the Treatment of Gastroesophageal Reflux Disease**    313

*Steve Swann*

19.1	Introduction	313
19.2	History	313
19.3	Synthesis	316
19.4	Mode of Action	319
19.5	Structure–Activity Relationships	320
	References	324

## **Part VI    Metabolic Diseases**    327

## 20      **Thiazolidinedione-Based Insulin Sensitizers:PPAR- $\gamma$ Agonists for the Treatment of Type 2 Diabetes**    329

*Steven Richards*

20.1	Introduction	329
20.2	History	329
20.3	Synthesis	337
20.4	Mode of Action	343
20.5	Structure–Activity Relationship	344
	References	345

## **Index**    349